AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements
AIkido Pharma Inc. (Nasdaq: AIKI) announced on January 22, 2021, that it has regained compliance with NASDAQ's minimum bid price requirement of $1.00 for continued listing. The Company achieved this following a closing bid price above $1.00 for 10 consecutive business days. CEO Anthony Hayes emphasized their commitment to maintain the NASDAQ listing and their efforts in developing effective pharmaceutical solutions through artificial intelligence technologies.
- Regained compliance with NASDAQ listing requirements, meeting the $1.00 minimum bid price.
- Ten consecutive business days of closing bid price at or above $1.00.
- Commitment to utilize AI technologies in pharmaceutical development.
- None.
NEW YORK, Jan. 22, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that on January 22, 2021, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that it has regained compliance with the
"We are fully committed to maintaining our Nasdaq listing and value the opportunity to reach a large and diverse community of investors as we continue our efforts to deploy our artificial intelligences technologies for the development of effective pharmaceutical solutions," commented Mr. Anthony Hayes, CEO of AIkido.
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.:
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-inc-regains-compliance-with-nasdaq-listing-requirements-301213309.html
SOURCE AIkido Pharma Inc.
FAQ
What compliance milestone did AIkido Pharma achieve on January 22, 2021?
How long did AIkido Pharma maintain its closing bid price to regain NASDAQ compliance?
What is the stock symbol for AIkido Pharma?
Who is the CEO of AIkido Pharma?
